Electrocompetent cells are chemically treated bacterial cells that are able to take up foreign DNA material through the application of an electric field (electroporation). They are utilized for cloning and transformation techniques in molecular and cellular biology. Electrocompetent cells offer advantages such as ease of preparation, high transformation efficiency and reliability over chemically competent cells. The growing demand for molecular cloning and engineering of valuable genetic constructs is propelling the usage of electrocompetent cells in various applications such as DNA library construction, protein expression and recombinant DNA technology.
The Global Electrocompetent Cells Market is estimated to be valued at US$ 2.07 Bn in 2024 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the Electrocompetent Cells are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., QIAGEN N.V., New England Biolabs, Inc., GenScript Biotech Corporation, Lucigen Corporation, Takara Bio Inc., Delphi Genetics S.A., IBA GmbH, Scarab Genomics LLC, Zymo Research Corporation, Bioline GmbH (Meridian Bioscience), and SelectScience. Electrocompetent cells product offerings from leading players coupled with their strategic collaborations & partnerships are enabling expansion of their geographic presence.
The rising R&D outsourcing in pharmaceutical and biotechnology industries present significant growth opportunities for electrocompetent cells market players. Additionally, growing demand for site-directed mutagenesis, protein expression and next generation sequencing assays in research and diagnostics is augmenting the overall market growth. Players are expanding their manufacturing facilities and distribution networks across major markets to leverage the lucrative opportunities in the global electrocompetent cells industry.
Market drivers: Increasing research investments from pharmaceutical and biotechnology players into areas such as gene therapy, recombinant DNA technology and synthetic biology is the key driver. Growing demand for plasmid DNA isolation and molecular cloning for applications such as DNA library preparation and site directed mutagenesis is also propelling the electrocompetent cells market growth.
Market restraints: Challenges in achieving high transformation efficiencies for certain bacterial strains and larger DNA fragments act as a restraint. Additionally, availability of alternative competent cell preparation methods impacts the overall electrocompetent cells market demand to some extent.
Segment Analysis
The electrocompetent cells market is dominated by the chemically competent cells segment. This segment holds the largest market share as chemically competent cells provide high transformation efficiency and are easy to prepare. They can uptake extracellular DNA present in the solution during the electroporation process. The commercially available chemically competent cells have optimized composition to increase the transformation efficiency thereby making them popular among researchers for routine subcloning and other applications.
Electrocompetent E.coli cells which are most commonly used bacterial cells for transformation also have significant demand. E.coli is easy to grow and manipulate genetically. It remains the preferred host for molecular cloning and protein expression. Though E.coli transformation using electroporation is more complex than chemical transformation, it provides higher transformation efficiency without toxic chemical treatment of cells.
Global Analysis
The North American region dominates the global electrocompetent cells market owing to extensive research and development activities in the fields of molecular biology and biotechnology. Presence of leading market players and availability of state-of-the-art research infrastructure and laboratories have boosted the adoption of electrocompetent cells in this region. The Asia Pacific region is anticipated to exhibit the fastest growth over the forecast period due to increasing government initiatives to strengthen biotechnology research. Rising investments by market players to tap the opportunities offered by emerging economies of China, India, and South Korea will aid the market expansion in Asia Pacific. Rapid establishment of new research facilities and upgradation of existing infrastructure are contributing to the regional market growth.
No comments:
Post a Comment